Pill vs. shot: which blood thinner do bladder cancer patients prefer after surgery?
NCT ID NCT06243510
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial compared two blood thinners—apixaban (a pill) and enoxaparin (a shot)—in 126 bladder cancer patients after bladder removal surgery. The goal was to see which one patients were more likely to take as prescribed, which they preferred, and what it cost them. Participants took their assigned drug at home for 30 days and answered surveys by phone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apixaban and enoxaparin
What this could lead to
If successful, this could show that apixaban is easier for patients to take at home than enoxaparin after bladder cancer surgery, potentially improving clot prevention.
What could go wrong
This is a small, completed study focused on patient adherence and cost, not on directly proving which drug prevents more clots. Results may not apply to all bladder cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States